Update On China’s National GMP Certification Progress
This article was originally published in PharmAsia News
At the end of October, 32.5% of sterile drug manufacturers and 20.3% of non-sterile manufacturers in China had passed GMP certification.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.